Crescent Biopharma Inc.
Organization details
- Legal name
- Crescent Biopharma Inc.
- Former names
- Glycomimetics Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Cayman Islands
- Headquarters city
- Waltham
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CBIO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001253689
Board of directors
-
Alexandra Balcom · DirectorSince 2025
-
Daniel M. Junius · DirectorSince 2023
-
David Charles Lubner · DirectorSince 2025
-
Harout Semerjian · Director · Chief Executive OfficerSince 2023
-
Jonathan Violin · DirectorSince 2025
-
Joshua T. Brumm · Director · Chief Executive OfficerSince 2025
-
Mark Alan Goldberg · DirectorSince 2023
-
Patricia S. Andrews · DirectorSince 2023
- Since 2025
-
Rachel K. King · DirectorSince 2023
-
Scott Koenig · DirectorSince 2023
-
Scott Thomas Jackson · DirectorSince 2023
-
Susan Moran · DirectorSince 2025
-
Timothy R. Pearson · DirectorSince 2023
- Since 2025
Chief executives
Director election results
Annual meeting of June 5, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
83.7%
Board connections
13 of this board's directors also sit on 21 other boards. 21 are in the same sector.
-
Dianthus Therapeutics Inc. Same sectorvia Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
-
Korsana Biosciences Inc. Same sectorvia Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
-
Viridian Therapeutics Inc. Same sectorvia Jonathan Violin, Peter Evan Harwin and Tomas Kiselak
-
Dyne Therapeutics Inc. Same sectorvia David Charles Lubner and Joshua T. Brumm
-
Geron Corporation Same sectorvia Harout Semerjian and Patricia S. Andrews
-
Jade Biosciences Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
MacroGenics Inc. Same sectorvia Scott Koenig and Scott Thomas Jackson
-
Oruka Therapeutics Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Spyre Therapeutics Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Zenas BioPharma Inc. Same sectorvia Peter Evan Harwin and Tomas Kiselak
-
Braveheart Bio Inc. Same sectorvia David Charles Lubner
-
Cogent Biosciences Inc. Same sectorvia Peter Evan Harwin
-
Damora Therapeutics Inc. Same sectorvia Peter Evan Harwin
-
Fulcrum Therapeutics Inc. Same sectorvia Rachel K. King
-
IDEXX Laboratories Inc. Same sectorvia Daniel M. Junius
-
Korro Bio Inc. Same sectorvia Timothy R. Pearson
-
Novavax Inc. Same sectorvia Rachel K. King
-
Oncolytics Biotech Inc. Same sectorvia Patricia S. Andrews
-
Spero Therapeutics Inc. Same sectorvia Scott Thomas Jackson
-
Tyra Biosciences Inc. Same sectorvia Susan Moran
-
Vor Biopharma Inc. Same sectorvia David Charles Lubner
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $30,612,625
- 2 purchases by 2 insiders
- Sold, last 12 months
- $1,511,627
- 16 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 18, 2026 | Joshua T. Brumm Director, Officer (Chief Executive Officer) | Open-market sale | −7,837 | $16.71 | $130,956 |
| Sep 18, 2026 | McNeill Jonathan Officer (President and COO) | Open-market sale | −3,839 | $16.71 | $64,150 |
| Sep 16, 2026 | Bispham Barbara Harlin Officer (See Remarks) | Open-market sale | −620 | $17.90 | $11,098 |
| Sep 16, 2026 | Joshua T. Brumm Director, Officer (Chief Executive Officer) | Open-market sale | −1,610 | $17.90 | $28,819 |
| Sep 16, 2026 | McNeill Jonathan Officer (President and COO) | Open-market sale | −731 | $17.90 | $13,085 |
| Sep 16, 2026 | Scalzo Richard William Officer (Chief Financial Officer) | Open-market sale | −568 | $17.90 | $10,167 |
| Sep 16, 2026 | Im Ellie Eunkyung Officer (Chief Medical Officer) | Open-market sale | −623 | $17.90 | $11,152 |
| Sep 16, 2026 | Pinkas Jan Officer (Chief Scientific Officer) | Open-market sale | −658 | $17.90 | $11,778 |
| Sep 16, 2026 | Lynch Ryan Officer (See Remarks) | Open-market sale | −240 | $17.90 | $4,296 |
| Jul 16, 2026 | Fairmount Healthcare Fund II L.P. Director, 10% owner | Open-market purchase | +853,450 | $14.50 | $12,375,025 |
| Jun 22, 2026 | Lynch Ryan Officer (See Remarks) | Open-market sale | −465 | $17.99 | $8,365 |
| Jun 22, 2026 | Pinkas Jan Officer (Chief Scientific Officer) | Open-market sale | −1,288 | $17.99 | $23,171 |
| Jun 22, 2026 | Scalzo Richard William Officer (Chief Financial Officer) | Open-market sale | −1,112 | $17.99 | $20,005 |
| Jun 22, 2026 | Bispham Barbara Harlin Officer (See Remarks) | Open-market sale | −1,218 | $17.99 | $21,912 |
| Jun 22, 2026 | Im Ellie Eunkyung Officer (Chief Medical Officer) | Open-market sale | −1,219 | $17.99 | $21,930 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Crescent Biopharma Inc.
Who is the CEO of Crescent Biopharma Inc.?
Joshua T. Brumm has been Crescent Biopharma Inc.'s Chief Executive Officer since June 2025.
How many directors are on Crescent Biopharma Inc.'s board?
Crescent Biopharma Inc.'s board has 15 directors: Alexandra Balcom, Daniel M. Junius, David Charles Lubner, Harout Semerjian, Jonathan Violin, Joshua T. Brumm, Mark Alan Goldberg, Patricia S. Andrews, Peter Evan Harwin, Rachel K. King and 5 others.
Are Crescent Biopharma Inc. insiders buying or selling shares?
Over the last 12 months, Crescent Biopharma Inc. insiders bought $30.6 million of shares in 2 purchases and sold $1.5 million of shares in 16 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="crescent-biopharma-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.